Logo

Medison Pharma Enters into an Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo (cemiplimab) Globally for Cancer Treatment

Share this

Medison Pharma Enters into an Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo (cemiplimab) Globally for Cancer Treatment

Shots:

  • Medison & Regeneron will jointly commercialize Libtayo in selected European markets & additional markets globally for indications incl. cutaneous squamous cell carcinoma, advanced basal cell carcinoma, NSCLC & cervical cancer
  • As per the agreement, the companies will jointly collaborate with all stakeholders & regulatory authorities to transfer the commercialization activities for Libtayo to Medison during H1’24. Earlier in Jul 2022, Regeneron acquired the exclusive worldwide, development, commercialization & manufacturing rights for Libtayo from Sanofi
  • Libtayo is a fully human mAb that functions by targeting the immune checkpoint inhibitor receptor PD-1 on T cells, developed using Regeneron's VelocImmune technology

Ref: Medison Pharma | Image: Medison Pharma

Related News:- Regeneron Reports Positive Results of Odronextamab in P-II (ELM-2) Trial for the Treatment of Follicular Lymphoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions